News

Late last year, Open AI's ChatGPT introduced the wider world to the immense power of artificial intelligence (AI). However, pharmaceutical companies have been experimenting with various forms of

Shares of Orchestra BioMed Holdings (NASDAQ: OBIO) were up more than 16% as of 1:30 p.m. on Wednesday, as investors piled in on what looked like a bargain after the healthcare stock hit a low the

AT&T (NYSE: T) is one of the largest telecom companies in the United States, but it only has a market cap of about $110 billion. That makes it much smaller than the tech titans that have entered the

The stock market has treated investors well so far in 2023, and although the past couple of weeks have been a bit more turbulent, the Nasdaq Composite (NASDAQINDEX: ^IXIC) gave Wall Street a gain of

AbbVie (NYSE: ABBV) is facing a tough year ahead. The company's blockbuster drug Humira, which treats various autoimmune conditions such as rheumatoid arthritis, psoriasis, and Crohn's disease, will

There are plenty of well-known biotech giants that look like solid investments. But targeting smaller and relatively unknown companies in the industry could provide much juicier returns over the

From June 15 through Monday, shares of Nio (NYSE: NIO) ended each trading session lower than where they had finished the day before. On Tuesday, however, the China-based electric vehicle (EV) maker

Clinical-stage biotech Viking Therapeutics (NASDAQ: VKTX) is having another tough trading session. As of 1:40 p.m. ET Tuesday, Viking's stock was down by 19.8% on higher-than-normal volume

On Monday, Snowflake (NYSE: SNOW) and Nvidia (NASDAQ: NVDA) announced a partnership at the Snowflake Summit 2023. "Snowflake's partnership with NVIDIA will bring high-performance machine learning

Viking Therapeutics' (NASDAQ: VKTX) shares were down by 9.9% on heavy volume as of 11:14 a.m. ET on Monday. This sizable drop was due to Pfizer's (NYSE: PFE) announcement that it will advance its

Shares of Structure Therapeutics (NASDAQ: GPCR) closed up 18.35% on Monday after the clinical-stage biotech received what is perceived to be good news from Pfizer and a boost from an analyst. The

Amgen (NASDAQ: AMGN) stock came under renewed pressure on Monday, several days after more regulators piled on to block a major acquisition announced by the company. The immediate catalyst was a

Pfizer (NYSE: PFE) is having a rough session in early trading Monday. Specifically, the drugmaker's shares were down by 5.5% on heavy volume as of 10:24 a.m. ET Monday morning. 

The big dip came

Buying low-priced growth stocks ($10 or below) can be risky. Companies with bargain-basement share prices tend to have weak balance sheets, highly uncertain outlooks, and limited financing

Dividend-paying pharmaceutical stocks have an outstanding track record of producing market-beating returns on capital. The core reason is that major drug manufacturers tend to generate enormous free

Sometimes, a company hits a stumbling block -- or several of them. The stock plummets, and investors lose faith. But, in some cases, these down-on-their luck companies are able to turn things

Michael Thomsen is the author of Cage Kings: How an Unlikely Group of Moguls, Champions, and Hustlers Transformed the UFC Into a $10 Billion Industry.

Motley Fool host Ricky Mulvey caught up with

What's small today could become huge in the future. That's especially true in the high-stakes world of biopharmaceutical companies. Three Fool.com contributors identified what they believe could be

What's the biggest knock against many high-yield dividend stocks? Probably that either the dividend or the share price is likely to sink sooner or later. That means that you often won't want to own

Sometimes even the professionals put the horse before the cart. For instance, Wall Street analysts are currently predicting that shares of the gene editing therapy biotech Intellia Therapeutics

Shares of life sciences company Abcam (NASDAQ: ABCM) were up 13.7% Friday afternoon after rising more than 14.6% earlier in the day. The impetus for the rise was the company's board of directors